Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Expands MEND Clinical Trial in Covid-19 and Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cynata Therapeutics"},{"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals to Present at World Microbe Forum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Recce Pharmaceuticals"},{"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Immuron"}]

Immuron

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

Details:

IMM-529, an oral compound taken three times consisting of combination of polyclonal AB targeting Clostridium-Difficile's toxin B responsible for clinical manifestation of disease, as well as spores and vegetative cells which are thought to be primary cause of recurrences.

Lead Product(s): IMM-529

Therapeutic Area: Infections and Infectious Diseases Product Name: IMM-529

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2022

ASK
US

Upload
your Pipeline Activity

Recce Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Recce Pharmaceuticals to Present at World Microbe Forum

Details:

Company’s lead synthetic anti-infective compound, RECCE® 327, and its novel, multi-layered mechanism of action (MoA) at the World Microbe Forum being held virtually on June 20-24, 2021.

Lead Product(s): R327

Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 21, 2021

ASK
US

Upload
your Pipeline Activity

Cynata Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cynata Expands MEND Clinical Trial in Covid-19 and Respiratory Failure

Details:

In the initial stage, the trial was designed to assess the early efficacy of Cymerus MSCs in Covid-19 patients admitted to intensive care. The trial will now analyse the early efficacy of Cymerus MSCs in patients with respiratory failure.

Lead Product(s): CYP-001

Therapeutic Area: Infections and Infectious Diseases Product Name: Cymerus MSCs

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY